Your browser doesn't support javascript.
The pharmacokinetic property and pharmacological activity of acteoside: A review.
Xiao, Yaosheng; Ren, Qun; Wu, Longhuo.
  • Xiao Y; Department of Orthopaetics, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
  • Ren Q; College of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
  • Wu L; College of Pharmacy, Gannan Medical University, Ganzhou 341000, China. Electronic address: longhw@gmu.edu.cn.
Biomed Pharmacother ; 153: 113296, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1894813
ABSTRACT
Acteoside (AC), a phenylpropanoid glycoside isolated from many dicotyledonous plants, has been demonstrated various pharmacological activities, including anti-oxidation, anti-inflammation, anti-cancer, neuroprotection, cardiovascular protection, anti-diabetes, bone and cartilage protection, hepatoprotection, and anti-microorganism. However, AC has a poor bioavailability, which can be potentially improved by different strategies. The health-promoting characteristics of AC can be attributed to its mediation in many signaling pathways, such as MAPK, NF-κB, PI3K/AKT, TGFß/Smad, and AMPK/mTOR. Interestingly, docking simulation study indicates that AC can be an effective candidate to inhibit the activity of SARS-CoV2 main protease and protect against COVID-19. Many clinical trials for AC have been investigated, and it shows great potentials in drug development.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Phosphatidylinositol 3-Kinases / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2022 Document Type: Article Affiliation country: J.biopha.2022.113296

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Phosphatidylinositol 3-Kinases / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2022 Document Type: Article Affiliation country: J.biopha.2022.113296